CNCR vs. OLGAX

Last updated Jun 3, 2026

CNCR (Loncar Cancer Immunotherapy ETF) and OLGAX (JPMorgan Large Cap Growth Fund Class A) are both funds - CNCR is a Health & Biotech Equities fund tracking the Loncar Cancer Immunotherapy Index, while OLGAX is a Large Cap Growth Equities fund managed by JPMorgan. CNCR charges 0.79%/yr vs 1.01%/yr for OLGAX.

Performance

CNCR vs. OLGAX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and JPMorgan Large Cap Growth Fund Class A (OLGAX). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

OLGAX

• 1D: 0.36%
• 1M: 5.75%
• YTD: 7.03%
• 6M: 5.72%
• 1Y: 20.87%
• 3Y*: 23.21%
• 5Y*: 13.09%
• 10Y*: 19.50%

*Multi-year figures are annualized to reflect compound growth (CAGR)

CNCR vs. OLGAX - Yearly Performance Comparison

	2026 (YTD)
CNCR Loncar Cancer Immunotherapy ETF	0.00%
OLGAX JPMorgan Large Cap Growth Fund Class A	9.66%

Return for Risk

CNCR vs. OLGAX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

OLGAX

OLGAX Risk / Return Rank: 18
OLGAX Sharpe Ratio Rank: 22
OLGAX Sortino Ratio Rank: 20
OLGAX Omega Ratio Rank: 21
OLGAX Calmar Ratio Rank: 13
OLGAX Martin Ratio Rank: 12

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. OLGAX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and JPMorgan Large Cap Growth Fund Class A (OLGAX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	CNCR	OLGAX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	1.40	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.65	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.91	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.50	—

Drawdowns

CNCR vs. OLGAX - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum OLGAX drawdown of -63.25%. Use the drawdown chart below to compare losses from any high point for CNCR and OLGAX.

Drawdown Indicators

	CNCR	OLGAX	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-63.25%	+63.25%
Max Drawdown (1Y) Largest decline over 1 year	—	-16.92%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-21.55%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-31.34%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-31.87%	—
Current Drawdown Current decline from peak	0.00%	0.00%	0.00%
Average Drawdown Average peak-to-trough decline	0.00%	-18.71%	+18.71%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	5.94%	—

Volatility

Volatility by Period

	CNCR	OLGAX	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	3.85%	—
Volatility (6M) Calculated over the trailing 6-month period	—	11.22%	—
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	15.62%	-15.62%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	20.18%	-20.18%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	21.58%	-21.58%

CNCR vs. OLGAX - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is lower than OLGAX's 1.01% expense ratio.

Dividends

CNCR vs. OLGAX - Dividend Comparison

CNCR has not paid dividends to shareholders, while OLGAX's dividend yield for the trailing twelve months is around 11.04%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
OLGAX JPMorgan Large Cap Growth Fund Class A	11.04%	11.82%	2.06%	0.00%	3.20%	15.30%	5.32%	13.03%	16.18%	14.92%	9.94%	4.51%